Karo Bio

December 2010

TRANSAKTION

A rights share issue providing SEK 300 million for funding a phase III trial of the Company´s main development project, eprotirome.

FÖRETAGET

Karo Bio is a Swedish pharmaceutical company which since 1986 has focused on the nuclear receptor area generating an innovative project pipeline. The leading compound eprotirome enters clinical phase III development as a dyslipidemia drug with strong phase II data and a unique mechanism of action.

AKTIEÄGARE

A public company listed on Nasdaq Small Cap OMX.